多囊卵巢综合征不孕患者血清生长素水平变化及其与胰岛素抵抗的关系被引量：6

Relation between serum Ghrelin level and insulin resistance in infertility patients with PCOS

下载PDF

导出

摘要目的研究多囊卵巢综合征(PCOS)不孕患者血清生长素(Ghrelin)水平的变化及其与胰岛素抵抗(IR)的关系。方法选择98例PCOS不孕患者(PCOS组)及72例非PCOS不孕患者(非PCOS组),比较两组患者的体重指数(BMI)、血清Ghrelin、血糖、胰岛素、稳态模型胰岛素抵抗指数(HOMA-IR)间的相互关系。血清Ghrelin采用ELISA法测定,空腹血浆葡萄糖(FPG)采用葡萄糖氧化酶法测定,空腹胰岛素(FIns)采用化学发光法测定。结果 PCOS组血清Ghrelin水平(pg/ml)明显低于非PCOS组[(442.56±221.71)vs(697.41±157.84),P<0.05]。PCOS组的HOMA-IR高于非PCOS组[(3.84±1.23)vs(2.14±0.77),P<0.05]。Person相关分析表明,PCOS组血清Ghrelin水平与HOMA-IR呈负相关(r=-0.48,P<0.01)。结论PCOS不孕患者血清Ghrelin水平降低,并且其降低与IR密切相关。提示Ghrelin可能参与PCOS不孕患者胰岛素抵抗的发生与发展。 Objective To explore the relationship between serum Ghrelin level and insulin resistance in in-fertility patients with PCOS.Methods Ninety-eight cases of PCOS （ PCOS group） and seventy-two cases of non PCOS （ non PCOS group） for first time visiting our hospital due to infertility from January 2010 to December 2012 were selected.The BMI, serum Ghrelin level, and the related anthropometric indexes were detected.Results The serum Ghrelin levels in PCOS patients were lower than non PCOS patients [ （ 442.56 ±221.71 ） pg/ml vs （ 697.41 ± 157.84）pg/ml, P〈0.05].The HOMA-IR was higher in PCOS group compared to non PCOS group[（3.84 ±1.23） vs （2.14 ±0.77）, P〈0.05].Pearson correlation analysis showed that serum Ghrelin level was negatively correlated with HOMA-IR in PCOS patients（r=-0.48, P〈0.01）.Conclusion The serum Ghrelin level in infertility patients with PCOS is evidently lower than that in non PCOS infertility patients.Ghrelin level was negatively correlated with HOMA-IR in PCOS patients.Thus indicated that Ghrelin may promote the development of IR in infertility patients with PCOS.

作者黄红艺何冰莫云刘杨桦张团英张凤兰

机构地区广西壮族自治区人民医院生殖中心广东医学院附属医院妇产科

出处《中国临床新医学》 2014年第10期902-904,共3页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基金广西卫生厅科研课题(编号:桂卫Z2013383)

关键词多囊卵巢综合征胰岛素抵抗不孕生长素 Polycystic ovary syndrome（PCOS） Insulin resistance（IR） Infertility Ghrelin

分类号 R711 [医药卫生—妇产科学]

引文网络
相关文献

参考文献11

1De Leo V A, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome [ J ]. Endocr Rev, 2003,24 (5) : 633 -667.
2Ovalle F, Azziz R. Insulin resistance, polycystie ovary syndrome, and type 2 diabetes mellitus[ J]. Fertil Stefil, 2002,77(6) : 1095 - 1105.
3Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone- releasing acylated peptide from stomach [ J ]. Nature, 1999, 402 (6762) : 656 - 660.
4Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang Ⅱ effects in mouse models of atherosclerosis[ J]. J Clin Invest, 2008, 118(10) : 3343 -3354.
5Fenaandez-Femandez R, Tena-Sempere M, Roa J, et al. Direct stim- ulatory effect of ghrelin on pituitary release of LH through a nitric ox- ide-dependent mechanism that is modulated by estregen[ J]. Repro- duction, 2007,133 (6) : 1223 - 1232.
6Gasco V, Beccuti G, Marotta F, et "al. Endocrine and metabolic ac- tions of ghrelin[J]. Endocr Dev, 2010,17 : 86 -95.
7Reimer MK, Pacini G, Ahren B. Dose-dependent inhibition by ghre- lin of insulin secretion in the mouse [ J]. Endocrinology, 2003,144 (3) : 916 -921.
8Amini P, Wadden D, Cahill F, et al. Serum acylated ghrelin is neg- atively correlated with the insulin resistance in the CODING study [J]. PLoSOne, 2012,7(9):456-457.
9Rittmaster RS, Deshwal N, Lehman L. The role of adrenal hyperan- drogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome[ J]. J Clin Endocrinol Metab, 1993. 76 (5) : 1295 -1300.
10Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma [ J ]. Lancet, 2003,361 (9371) : 1810 - 1812.

二级参考文献10

1李春蕊,张晶,刘文励,张木勋.罗格列酮对实验性2型糖尿病合并高脂血症大鼠骨骼肌组织IRS-1及GLUT4表达的调节[J].中国病理生理杂志,2007,23(5):900-903. 被引量：6
2Sozen I, Arici A. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome [ J ]. Obstet Gynecol, 2000, 56(5): 321-328.
3Wu XK, Zhou SY, Liu JX. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome [J]. Fertil Steril, 2003,80(4):954-965.
4Wu XK, Sallinen K, Anttila L,et al. Expression of insulin - receptor substrate - 1 and - 2 in ovariaes from women with PCOS and from controls [ J ]. Fertil Steril, 2000,74 (3) :564 -572.
5Cataldo NA, Abbasi F, McLaughlin TL, et al. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin - resistant women with polycystic ovary syndrome [ J ]. Hum Reprod, 2006,21 ( 1 ) : 109 - 120.
6BeUi SH, Graffigna MN, Oneto A, et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome [J]. Fertil Steril, 2004,81(3) :624 -629.
7Rotterdam. Revised 2003 consensus on diagnostic criteria and long - term health risks related to polycystic ovary syndrome[ J]. Fertil Steril, 2004,81 ( 1 ) : 19 - 25.
8Moran C, Huerta R, Conway Myers BA, et al. Altered autophosphorylation of the insulin receptor in the ovary of a women with PCOS [J]. Fertil Steril, 2001,75(4) :635 - 628.
9Pessin JE, Saltiel AR. Signaling pathways in insulin action : molecular targets of insulin resistance[ J]. J Clin Invest, 2000,106( 1 ) : 165 - 169.
10Yen HW, Jakimiuk AJ, Munir I, et al. Selective alterations in insulin receptor substrates - 1, - 2 and - 4 in theca but not granulosa cells from polycystic ovaries [J]. Mole Hum Reprod, 2004, 10(7) : 473 -479.